Critical reviews in oncology/hematology
-
Crit. Rev. Oncol. Hematol. · Apr 2014
ReviewMetastatic castration resistant prostate cancer: current strategies of management in the Middle East.
Although most patients with prostate cancer respond to initial androgen-deprivation therapy, progression to castration-resistant prostate cancer (CRPC) is almost inevitable. In 2004, the docetaxel/prednisone regimen was approved for the management of patients with metastatic CRPC, becoming the standard first-line therapy. ⋯ Such drugs are either already marketed or about to be marketed in the Middle East. Data supporting the approval of each of these agents are described in this review, as are recent approaches to the treatment of metastatic CRPC.